Vaccine · Immune activation · developed by Pfizer
PG4 Multivalent Vaccine is a multivalent pneumococcal vaccine intended to induce immunity against Streptococcus pneumoniae infection. It is being studied in pneumococcal disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07794748 | Phase 3 | Pneumococcal Disease | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pneumococcal Disease
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →